Topics

Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator announces second round of awards

19:00 EST 3 Dec 2019 | AAAS

(Alzheimer's Drug Discovery Foundation) The Alzheimer's Drug Discovery Foundation (ADDF) announced 6 new investments totaling $6 million through its Diagnostics Accelerator initiative. These current awards include research for blood tests in various stages of development, with one close to becoming a viable diagnostic tool for early detection of Alzheimer's disease. Other research efforts include the development of ocular and genetic tests that will aid in diagnosis and appropriate clinical trial design for intervention and disease monitoring for Alzheimer's disease and related dementias.

Original Article: Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator announces second round of awards

NEXT ARTICLE

More From BioPortfolio on "Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator announces second round of awards"

Quick Search

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...